| Literature DB >> 35683440 |
Vânia Rocha1,2, Jorge Cabral3, Sara Souto-Miranda1,2, Ana Filipa Machado1,2, Cristina Jácome4,5, Joana Cruz1,6, Vitória Martins7, Paula Simão8, Maria Aurora Mendes1,9, Vera Afreixo3, Alda Marques1,2.
Abstract
Functional status is an important and meaningful outcome in people with chronic obstructive pulmonary disease (COPD), although its measurement is not embedded in routine clinical assessments. This study described the functional status of people with COPD using the 1-min sit-to-stand test (1minSTS) over a 6-month period and the examined sociodemographic and clinical characteristics associated with this outcome. Data from a prospective study including people with COPD were analyzed. Functional status was assessed monthly with the 1minSTS over 6 months. Linear-mixed effect models assessed the 1minSTS number of repetitions mean change. One-hundred and eight participants (82.4% men; 66.9 ± 9.5 years) were included. A significantly lower number of repetitions in the 1minSTS over the 6-month period was associated with being female (estimate: -4.69, 95%CI: -8.20; -1.18), being older (estimate: -0.56, 95%CI: -0.77; -0.34), having higher BMI (estimate: -0.55, 95%CI: -0.81; -0.28) and having higher activity-related dyspnea (estimate: -2.04, 95%CI: -3.25; -0.83). Half of the participants showed improvements above three repetitions in the 1minSTS over the 6-month period, independently of their baseline impairment (1minSTS < 70% predicted: 52.5%; ≥70% predicted: 54.4%). To conclude, monthly follow-up assessments were associated with clinically relevant benefits in the functional status of people with COPD. Age, body composition, and activity-related dyspnea were the main predictors of functional status over time. Further research is needed to corroborate our findings and to support the beneficial effects of regular COPD monitoring.Entities:
Keywords: COPD; evaluation and monitoring; field tests; functional status; one-minute sit-to-stand test
Year: 2022 PMID: 35683440 PMCID: PMC9181503 DOI: 10.3390/jcm11113052
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Baseline characteristics of participants with chronic obstructive pulmonary disease (n = 108).
| Characteristics (n = 108) | |
|---|---|
| 66.9 (9.5) | |
|
| 89 (82.4) |
| 26.9 (4.4) | |
| ≤4 (ISCED 0–1) | 52 (48.1) |
| 5–9 (ISCED 2) | 29 (26.9) |
| ≥10 (ISCED 3–8) | 27 (25.0) |
|
| |
| Never | 13 (12.0) |
| Former | 81 (75.0) |
| Current | 14 (13.0) |
| 45.0 (17.7–75.9) | |
| 1 (1.0; 2.0) | |
| 0 | 79 (73.1) |
| 1 | 10 (9.3) |
| >1 | 19 (17.6) |
|
| |
| FEV1, % predicted—median (Q1–Q3) | 58.0 (41.0–75.0) |
| FEV1/FVC—median (Q1–Q3) | 54.7 (45.3–63.0) |
| GOLD grades | |
| 1 | 23 (21.3) |
| 2 | 44 (40.7) |
| 3 | 27 (25.0) |
| 4 | 13 (12.0) |
| 11.0 (8.0–18.0) | |
|
| 16 (15.0) |
|
| 18 (16.7) |
|
| |
| A | 39 (36.1) |
| B | 47 (43.5) |
| C | 1 (0.9) |
| D | 21 (19.4) |
|
| |
| Mild (1–2 points) | 25 (23.1) |
| Moderate (3–4 points) | 58 (53.8) |
| Severe (≥5 points) | 25 (23.1) |
|
| |
| Bronchodilators | |
| ICS | 11 (10.2) |
| LAMA | 23 (21.3) |
| SABA | 16 (14.8) |
| LABA | 10 (9.3) |
| SAMA | 1 (0.9) |
| Combination ICS/LABA | 31 (28.7) |
| Combination LABA/LAMA | 34 (31.5) |
| Combination LABA/LAMA/ICS | 2 (1.9) |
| Xanthines | 11 (10.2) |
| Expectorants | 6 (5.6) |
| LTRA | 5 (4.6) |
| Anti-fibrotics/ Immunosuppressants | 1 (0.9) |
| 25.5 (21.0–30.3) | |
| <70% predicted | 45 (41.7) |
| ≥70% predicted | 63 (58.3) |
Legend: Data are presented as n (%), unless otherwise stated. 1minSTS, one-minute sit-to-stand test; AECOPD, acute exacerbation of COPD; BMI, body mass index; CAT, COPD assessment test; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, global initiative for chronic obstructive lung disease; ICS, inhaled corticosteroids; ISCED, International Standard Classification of Education; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; LRTA, leukotriene receptor antagonist; PR, pulmonary rehabilitation; Q, quartile; mMRC, modified British medical council dyspnoea scale; SABA, short-acting beta-agonist; SAMA, short-acting muscarinic antagonist; SD, standard deviation.
Figure 1Number of repetitions in the one-minute sit-to-stand test (1minSTS) over 6 months. Time was defined as number of days between baseline and follow-up assessments; the green line represents the linear tendency, considering time a continuous variable; blue dots represent male patients and pink dots represent female patients; No.: number.
Factors associated with the number of repetitions in the one-minute sit-to-stand test (1minSTS) in people with chronic obstructive pulmonary disease (COPD) over the 6-month period (n = 108).
| (n = 108) | 1minSTS |
|---|---|
|
|
|
| (Intercept) |
|
| Sex (Female) |
|
| Age |
|
| BMI |
|
| mMRC |
|
| Time |
|
| Sex (Female) * Time | 0.02 (−2.57 × 10 −4; 0.03) |
| Age * Time |
|
|
| |
| σ2 | 9.84 |
| τ00 | 52.90Participant |
| τ11 | 0.01Participant.Time |
| ρ01 | 0.47Participant |
| Observations | 535 |
| Marginal/Conditional R2 | 0.37/0.92 |
Legend: 1minSTS, one-minute sit-to-stand test; CI, confidence interval; BMI, body mass index; mMRC, modified British medical council dyspnoea scale; σ2, residual variance; τ, random effect standard deviation; ρ, correlation between intercept and slope; ICC, intraclass correlation coefficient; R2, coefficient of determination; * interaction with; in bold: p-value < 0.05.
Figure 2Predicted values for the number of repetitions in the one-minute sit-to-stand test (1minSTS) in participants with chronic obstructive pulmonary disease. According to the model, the 1minSTS values were adjusted for male participants, body mass index of 25, mild Charlson comorbidity index score, 53.31% predicted of forced expiratory volume in one-second, and a score of 2 in the modified British medical research council dyspnoea scale.
Figure 3Change in the one-minute sit-to-stand (1minSTS) number of repetitions from the first to the sixth assessment in participants with baseline functional status impairment (i.e., 1minSTS < 70% predicted—represented as dots in the left side of the vertical dashed line) or without impairment (i.e., 1minSTS ≥ 70% predicted—represented as dots in the right side of the vertical dashed line).The vertical dashed line illustrates the established impairment cut-off; horizontal dashed lines illustrate the minimal clinically important differences interval (MCID): ±3 repetitions; green dots represent participants who had their number of repetitions increased above the MCID; yellow dots represent participants who had their number of repetitions similar or unchanged with time without reaching the MCID; red dots represent participants who had their number of repetitions decreased above the MCID.